Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity.
Beta-agonists used for treatment of obstructive lung disease have a variety of different structures but are typically classified by their intrinsic activities for stimulation of cAMP, and predictions are made concerning other downstream signals based on such a classification. We generated modified beta(2)-adrenergic receptors with insertions of energy donor and acceptor moieties to monitor agonist-promoted conformational changes of the receptor using intramolecular bioluminescence resonance energy transfer in live cells. These studies suggested unique conformations stabilized by various agonists that were not based on their classic intrinsic activities. To address the cellular consequences of these differences, G(s)-coupling, G(i)-coupling (p44/p42 activation), G protein-coupled receptor kinase-mediated receptor phosphorylation, internalization, and down-regulation were assessed in response to isoproterenol, albuterol, terbutaline, metaproterenol, salmeterol, formoterol, and fenoterol. In virtually every case, agonists did not maintain the classic rank order, indicating that distinct signaling is evoked by beta-agonists of different structures, which is unrelated to intrinsic activity. The extensive pleiotropy of agonist responses shown here suggests that classification of agonists by cAMP-based intrinsic activity is inadequate as it pertains to other intracellular events and that it may be possible to engineer a beta-agonist that stabilizes conformations that evoke an ideal portfolio of signals for therapeutic purposes.
Swift
Steven M
SM
Department of Medicine, Cardiopulmonary Genomics Program, University of Maryland School of Medicine, Baltimore, MD 21201-1075, USA.
Schwarb
Mary Rose
MR
Mihlbachler
Kathryn A
KA
Liggett
Stephen B
SB
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D006224:Cricetinae; D003412:Cricetulus; D000242:Cyclic AMP / Q000378:metabolism; D015536:Down-Regulation / Q000187:drug effects; D004705:Endocytosis / Q000187:drug effects; D006801:Humans; D008164:Luminescent Proteins / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000201:enzymology; D010766:Phosphorylation / Q000187:drug effects; D011487:Protein Conformation / Q000187:drug effects; D018343:Receptors, Adrenergic, beta-2 / Q000737:chemistry* / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects*; D013050:Spectrometry, Fluorescence
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D008164:Luminescent Proteins; D018343:Receptors, Adrenergic, beta-2; D000242:Cyclic AMP; D048052:Mitogen-Activated Protein Kinase 3